The mammoth consumer health deal Pfizer and GlaxoSmithKline struck last December is finally sealed. But things are looking markedly different at Pfizer than they did seven months ago—and that may not be a good thing, analysts say. More: Pfizer's GSK
read moreWhen Fresenius disclosed it was looking into Akorn’s data handling, investors were caught off guard. Now, Akorn investors secured a potential settlement over their losses. More: After Fresenius deal collapse, Akorn inks M settlement with investors over data integrity woes
read moreWith Celgene making the big move under Bristol-Myers Squibb’s umbrella, the drugmaker is looking to clear its books before the merger. Two antitrust settlements totaling more than $100 million will cross a couple of legal problems off its list. More:
read moreTakeda’s been cutting costs on one hand and raising cash on the other to pay off its Shire deal debt—and so far, it’s on track to hit those goals, executives said this week. And its annual cost-saving target is a
read moreFDA inspectors keep hitting replay for Dr. Reddy’s plants as they make their way through its manufacturing sites. They cite a facility and move on only to find India’s second-largest drugmaker making missteps at the next facility they check. More:
read moreThe NHS Confederation has penned a letter to Boris Johnson, the UK’s new prime minister. More: NHS Confederation addresses new PM over ‘unfinished business’ Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals